OncoCyte Corporation
OCX
$3.44
$0.051.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -33.51M | -13.49M | -4.53M | -9.13M | -15.99M |
| Total Depreciation and Amortization | 563.00K | 340.00K | 326.00K | 335.00K | 325.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.75M | 7.60M | -595.00K | 3.95M | 11.75M |
| Change in Net Operating Assets | -1.16M | -2.00K | -1.18M | 1.02M | -510.00K |
| Cash from Operations | -5.35M | -5.55M | -5.98M | -3.83M | -4.42M |
| Capital Expenditure | -214.00K | -87.00K | -191.00K | -24.00K | -264.00K |
| Sale of Property, Plant, and Equipment | 4.00K | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 367.00K |
| Cash from Investing | -210.00K | -87.00K | -191.00K | -24.00K | 103.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -82.00K | -86.00K | -33.00K | -- | -30.00K |
| Issuance of Common Stock | 11.99M | 18.00K | 15.81M | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | 0.00 | 0.00 | -5.39M | -- | 0.00 |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.07M | -187.00K | -538.00K | -- | 0.00 |
| Cash from Financing | 10.84M | -255.00K | 9.85M | -- | -30.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.27M | -5.89M | 3.68M | -3.85M | -4.35M |